153 related articles for article (PubMed ID: 37943279)
1. INDIVIDUAL ARTICLE: USCOM Algorithm for the Prevention and Management of Cutaneous Immunotherapy-Related Adverse Events.
Deutsch A; Lacouture M; Andriessen A; Choi JN; Ho AY; McLellan BN; Mitchell E; Leventhal JS
J Drugs Dermatol; 2023 Nov; 22(11):SF389716s3-SF389716s10. PubMed ID: 37943279
[TBL] [Abstract][Full Text] [Related]
2. United States Cutaneous Oncodermatology Management (USCOM) II: A Multidisciplinary-Guided Algorithm for the Prevention and Management of Acute Radiation Dermatitis in Cancer Patients.
Leventhal J; Lacouture M; Andriessen A; McLellan B; Ho A
J Drugs Dermatol; 2022 Nov; 21(11):SF3585693-SF35856914. PubMed ID: 36342740
[TBL] [Abstract][Full Text] [Related]
3. Management of Cutaneous Immune-Related Adverse Events in Patients With Cancer Treated With Immune Checkpoint Inhibitors: A Systematic Review.
Nadelmann ER; Yeh JE; Chen ST
JAMA Oncol; 2022 Jan; 8(1):130-138. PubMed ID: 34709352
[TBL] [Abstract][Full Text] [Related]
4. US Cutaneous Oncodermatology Management (USCOM): A Practical Algorithm.
Lacouture ME; Choi J; Ho A; Leventhal J; McLellan BN; Andriessen A; Sauder MB; Mitchell E
J Drugs Dermatol; 2021 Sep; 20(9):3ss-s19. PubMed ID: 34491030
[TBL] [Abstract][Full Text] [Related]
5. Cutaneous immune-related adverse events are associated with longer overall survival in advanced cancer patients on immune checkpoint inhibitors: a multi-institutional cohort study.
Zhang S; Tang K; Wan G; Nguyen N; Lu C; Ugwu-Dike P; Raval N; Seo J; Alexander NA; Jairath R; Phillipps J; Leung BW; Roster K; Chen W; Zubiri L; Boland G; Chen ST; Tsao H; Demehri S; LeBoeuf NR; Reynolds KL; Yu KH; Gusev A; Kwatra SG; Semenov YR
medRxiv; 2023 Jan; ():. PubMed ID: 36711758
[TBL] [Abstract][Full Text] [Related]
6. Association of Cutaneous Immune-Related Adverse Events With Increased Survival in Patients Treated With Anti-Programmed Cell Death 1 and Anti-Programmed Cell Death Ligand 1 Therapy.
Tang K; Seo J; Tiu BC; Le TK; Pahalyants V; Raval NS; Ugwu-Dike PO; Zubiri L; Naranbhai V; Carrington M; Gusev A; Reynolds KL; LeBoeuf NR; Asgari MM; Kwatra SG; Semenov YR
JAMA Dermatol; 2022 Feb; 158(2):189-193. PubMed ID: 35019948
[TBL] [Abstract][Full Text] [Related]
7. Cutaneous adverse events caused by immune checkpoint inhibitors.
Quach HT; Johnson DB; LeBoeuf NR; Zwerner JP; Dewan AK
J Am Acad Dermatol; 2021 Oct; 85(4):956-966. PubMed ID: 34332798
[TBL] [Abstract][Full Text] [Related]
8. How to recognize and manage skin toxicities associated with immune checkpoint inhibitors: a practical approach.
Kawsar A; Hussain K; Muinonen-Martin AJ; Fearfield L
Br J Dermatol; 2023 Oct; 189(Suppl 1):i3-i10. PubMed ID: 37903072
[TBL] [Abstract][Full Text] [Related]
9. Characterization and Prognostic Significance of Cutaneous Immune-Related Adverse Events in Indian Patients on Immune Checkpoint Inhibitor Therapy.
Duraisamy P; Panicker VV; Jose WM
Dermatol Pract Concept; 2023 Jul; 13(3):. PubMed ID: 37557151
[TBL] [Abstract][Full Text] [Related]
10. Clinical associations and classification of immune checkpoint inhibitor-induced cutaneous toxicities: a multicentre study from the European Academy of Dermatology and Venereology Task Force of Dermatology for Cancer Patients.
Nikolaou VA; Apalla Z; Carrera C; Fattore D; Sollena P; Riganti J; Segura S; Freites-Martinez A; Lallas K; Romano MC; Oikonomou C; Starace M; Dimopoulos MA; Kyrgidis A; Lazaridou E; Giavedoni P; Annunziata MC; Peris K; Echeverría M; Lopez-Tujillo E; Syrigos K; Papageorgiou C; Podlipnik S; Fabbrocini G; Torre AC; Kemanetzi C; Villa-Crespo L; Lallas A; Stratigos AJ; Sibaud V
Br J Dermatol; 2022 Dec; 187(6):962-969. PubMed ID: 35861701
[TBL] [Abstract][Full Text] [Related]
11. INDIVIDUAL ARTICLE: NECOM 3: A Practical Algorithm for the Management of Radiation Therapy-Related Acute Radiation Dermatitis.
Girnita A; Bjerring P; Kauppi S; Lynde CW; Sauder MB; Andriessen A
J Drugs Dermatol; 2023 Nov; 22(11):SF400354s3-SF400354s10. PubMed ID: 37943258
[TBL] [Abstract][Full Text] [Related]
12. Cutaneous immune-related adverse events are associated with longer overall survival in advanced cancer patients on immune checkpoint inhibitors: A multi-institutional cohort study.
Zhang S; Tang K; Wan G; Nguyen N; Lu C; Ugwu-Dike P; Raval N; Seo J; Alexander NA; Jairath R; Phillipps J; Leung BW; Roster K; Chen W; Zubiri L; Boland G; Chen ST; Tsao H; Demehri S; LeBoeuf NR; Reynolds KL; Yu KH; Gusev A; Kwatra SG; Semenov YR
J Am Acad Dermatol; 2023 May; 88(5):1024-1032. PubMed ID: 36736626
[TBL] [Abstract][Full Text] [Related]
13. FULL SUPPLEMENT: Skincare for Cancer Patients and Survivors.
J Drugs Dermatol; 2021 Sep; 20(9):2s-s18. PubMed ID: 34491029
[TBL] [Abstract][Full Text] [Related]
14. Immune checkpoint inhibitor-related dermatologic adverse events.
Geisler AN; Phillips GS; Barrios DM; Wu J; Leung DYM; Moy AP; Kern JA; Lacouture ME
J Am Acad Dermatol; 2020 Nov; 83(5):1255-1268. PubMed ID: 32454097
[TBL] [Abstract][Full Text] [Related]
15. Detection of novel therapies using a multi-national, multi-institutional registry of cutaneous immune-related adverse events and management.
Mital R; Otto TS; Savu A; Baumrin E; Cardones AR; Carlesimo M; Caro G; Freites-Martinez A; Hirner JP; Markova A; McLellan BN; Rossi A; Sauder MB; Seminario-Vidal L; Sibaud V; Owen DH; Dulmage BO; Chen ST; Kaffenberger BH
Int J Dermatol; 2023 Aug; 62(8):1020-1025. PubMed ID: 37203799
[TBL] [Abstract][Full Text] [Related]
16. Effect of dermatological consultation on survival in patients with checkpoint inhibitor-associated cutaneous toxicity.
Thompson LL; Li EB; Krasnow NA; Chang MS; Said JT; Molina GE; Polyakov NJ; Yoon J; Dee EC; Huang K; Blum AE; Kuchroo JR; Hinton AN; Reynolds KL; Chen ST
Br J Dermatol; 2021 Sep; 185(3):627-635. PubMed ID: 33733456
[TBL] [Abstract][Full Text] [Related]
17. Cutaneous Adverse Events and Cancer Survival Prognosis With Immune Checkpoint Inhibitor Treatment: A Systematic Review and Meta-Analysis.
Du Y; Wu W; Chen M; Dong Z; Wang F
JAMA Dermatol; 2023 Oct; 159(10):1093-1101. PubMed ID: 37672255
[TBL] [Abstract][Full Text] [Related]
18. Cutaneous immune-related adverse events: incidence rates, risk factors and association with extracutaneous toxicity. A prospective study of 189 patients treated with checkpoint inhibitors in a Spanish tertiary care hospital.
Juan-Carpena G; Martínez Banaclocha N; Palazón-Cabanes JC; Niveiro-de Jaime M; Betlloch-Mas I; Blanes-Martínez M
Clin Exp Dermatol; 2024 Feb; ():. PubMed ID: 38372424
[TBL] [Abstract][Full Text] [Related]
19. Cancer Type and Histology Influence Cutaneous Immunotherapy Toxicities: A Multi-Institutional Cohort Study.
Wan G; Khattab S; Leung BW; Zhang S; Nguyen N; Tran M; Lin C; Chang C; Alexander N; Jairath R; Phillipps J; Tang K; Rajeh A; Zubiri L; Chen ST; Demehri S; Yu KH; Gusev A; Kwatra SG; LeBoeuf NR; Reynolds KL; Semenov YR
Br J Dermatol; 2024 Feb; ():. PubMed ID: 38366637
[TBL] [Abstract][Full Text] [Related]
20. European recommendations for management of immune checkpoint inhibitors-derived dermatologic adverse events. The EADV task force 'Dermatology for cancer patients' position statement.
Apalla Z; Nikolaou V; Fattore D; Fabbrocini G; Freites-Martinez A; Sollena P; Lacouture M; Kraehenbuehl L; Stratigos A; Peris K; Lazaridou E; Richert B; Vigarios E; Riganti J; Baroudjian B; Filoni A; Dodiuk-Gad R; Lebbé C; Sibaud V
J Eur Acad Dermatol Venereol; 2022 Mar; 36(3):332-350. PubMed ID: 34910332
[TBL] [Abstract][Full Text] [Related]
[Next] [New Search]
